Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Adaptimmune Therapeutics Plc ADR shares valued at $950 were sold by Wood Gavin on Sep 02 ’25. At $0.01 per share, Wood Gavin sold 96,000 shares. The insider’s holdings dropped to 0 shares worth approximately $0.0 following the completion of this transaction.
Also, Gavin Wood purchased 16,000 shares, netting a total of over 942 in proceeds.
Before that, Bertrand William C JR had sold 207,000 shares from its account. In a trade valued at $2,091, the Chief Operating Officer traded Adaptimmune Therapeutics Plc ADR shares for $0.01 each. Upon closing the transaction, the insider’s holdings decreased to 207,000 shares, worth approximately $0.13 million.
As published in a research note from H.C. Wainwright on July 29, 2025, Adaptimmune Therapeutics Plc ADR [ADAP] has been rated down from a Buy to a Neutral. Analysts at Mizuho downgraded the stock from ‘”an Outperform”‘ to ‘”a Neutral”‘ outlook in a report released in late June. As of July 30, 2024, H.C. Wainwright has initiated its “Buy” rating for ADAP. Earlier on May 30, 2024, Scotiabank initiated its rating. Their recommendation was “a Sector outperform” for ADAP stock.
Analyzing ADAP Stock Performance
On last trading session, Adaptimmune Therapeutics Plc ADR [NASDAQ: ADAP] rose 6.52% to $0.13. The stock’s lowest price that day was $0.122, but it reached a high of $0.1333 in the same session. During the last five days, there has been a surge of approximately 1.57%. Over the course of the year, Adaptimmune Therapeutics Plc ADR shares have dropped approximately -86.43%. Shares of the company reached a 52-week high of $0.6850 on 01/06/25 and a 52-week low of $0.0403 on 09/08/25.
Support And Resistance Levels for Adaptimmune Therapeutics Plc ADR (ADAP)
According to the 24-hour chart, there is a support level at 0.1229, which, if violated, would cause prices to drop to 0.1167. In the upper region, resistance lies at 0.1343. The next price resistance is at 0.1395. RSI (Relative Strength Index) is 55.54 on the 14-day chart, showing neutral technical sentiment.
Is Adaptimmune Therapeutics Plc ADR subject to short interest?
Stocks of Adaptimmune Therapeutics Plc ADR saw a sharp rise in short interest on 2025-09-15 jumping by 11.98 million shares to 23.05 million. Data from Yahoo Finance shows that the short interest on 2025-08-15 was 11.07 million shares. A jump of 51.96% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 0.36 of the overall float, the days-to-cover ratio (short ratio) jumped to 0.36.
Which companies own the most shares of Adaptimmune Therapeutics Plc ADR (ADAP)?
In terms of Adaptimmune Therapeutics Plc ADR share price expectations, FactSet research, analysts set an average price target of 3 in the next 12 months, up nearly 2400.0% from the previous closing price of $0.12. Analysts anticipate Adaptimmune Therapeutics Plc ADR stock to reach 4 by 2025, with the lowest price target being 1. In spite of this, 6 analysts ranked Adaptimmune Therapeutics Plc ADR stock as Buy at the end of 2025. On March 24, 2023, Bryan Garnier assigned a price target of “a Buy” to the stock and initiated coverage with a $3.60.
